LivaNova Q2 top-line down 4%; reiterates guidance

LivaNova (LIVN +1.6%) Q2 results: Revenues: $277.2M (-3.6%); Cardiovascular: $172.2M (-2.4%); Neuromodulation: $104.3M (-5.8%); Other: $0.7M (+75.0%).

Net Loss: ($29.4M); Loss Per Share: ($0.61); Non-GAAP Net Income: $34.3M (-27.8%); Non-GAAP EPS: $0.70 (-27.1%); CF Ops: ($17.4M) (-135.9%).

2019 guidance: Revenue growth: 1% – 3% (unch); non-GAAP EPS: $3.00 – 3.10 (unch).

Previously: LivaNova PLC EPS beats by $0.05, beats on revenue (July 31)

https://seekingalpha.com/news/3484301-livanova-q2-top-line-4-percent-reiterates-guidance